logo

Xenon Pharmaceuticals Inc. (XENE)



Trade XENE now with
  Date
  Headline
1/28/2019 8:10:53 AM Xenon Provides Regulatory Updates On XEN007 And XEN1101
1/6/2019 9:07:08 PM Xenon Pharma Provides Corporate Update And Outlines Anticipated Key Milestone Events In 2019
12/3/2018 7:48:01 AM Xenon Announces Final Results Of XEN1101 Phase 1 Trial And Update On XEN901 Phase 1 Clinical Trial
9/17/2018 4:22:14 PM Xenon Pharmaceuticals Announces Closing Of Its $63 Mln Public Offering Of Common Shares
9/12/2018 9:20:44 PM Xenon Pharma Announces Pricing Of Its Underwritten Public Offering Of 4.50 Mln Shares At $14.00/shr
9/12/2018 4:02:51 PM Xenon Pharmaceuticals Announces Proposed Public Offering Of Common Shares
9/6/2018 6:39:51 AM Xenon Expands Ion Channel Neurology Pipeline With Addition Of XEN496, A “Phase 3 Ready” Potassium Channel Modulator
8/29/2018 6:06:07 AM Xenon Announces Positive XEN1101 Pharmacodynamic Data From Phase 1b TMS Study
5/15/2018 6:11:09 AM Xenon Presents Positive XEN1101 TMS Pharmacodynamic Phase 1 Data At 14th Eilat Conference
5/15/2018 6:05:44 AM Xenon Presents XEN901 Phase 1 Clinical Update And Supporting Pre-clinical Data At 14th Eilat Conference
3/28/2018 8:36:18 AM Xenon Confirms Closing Of Transaction With Teva And Announces Preferred Share Exchange Agreement With BVF Partners
  
 
>